

Pfizer Vaccines Reimbursement Support Services

A service to help confirm TRUMENBA® coverage

Indication

- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed

Important Safety Information

- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- In clinical studies, the most common solicited adverse reactions were pain at the injection site (≥85%), fatigue (≥40%), headache (≥35%), muscle pain (≥30%), and chills (≥15%)
- Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness has not been established in pregnant women

Click [here](#) for full Prescribing Information for TRUMENBA.

Pfizer Vaccines Reimbursement Support Services: Helping You Confirm **TRUMENBA®** [Meningococcal Group B Vaccine] Coverage for Patients 10–25 Years Old



Benefit Investigation

- Verify patient coverage via telephone or fax
- Most coverage verifications are completed the same day (maximum 48 hours)



Prior Authorization Support (if Needed)

- Identify necessary steps needed to gain valid prior authorization



Claim Denials/Appeals Support

- Gathering of necessary information for healthcare provider to file an appeal

Call: 1-866-744-3198

Fax: 1-866-744-3303

Monday–Friday

8:00 AM–8:00 PM (Eastern Time)

CPT* Code:

TRUMENBA® 90621

NDC Code:

TRUMENBA® Single Dose:
0005-0100-01

NDC=National Drug Code.

*CPT is a registered trademark of the American Medical Association (AMA).

The Reimbursement Hotline is a customer support program provided by Pfizer Vaccines. Pfizer requests that you use this service to help address health insurance coverage questions. Our sales representatives are not permitted to discuss reimbursement rates with healthcare providers.

Check the ACIP website <http://www.cdc.gov/vaccines/acip/> for the latest recommendations for serogroup B meningococcal (MenB) vaccinations

Indication

- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed

Selected Safety Information

- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- In clinical studies, the most common solicited adverse reactions were pain at the injection site (≥85%), fatigue (≥40%), headache (≥35%), muscle pain (≥30%), and chills (≥15%)

Please see full Important Safety Information on next page and click [here](#) for full Prescribing Information for TRUMENBA.

The Pfizer Reimbursement Hotline is available at:

1-866-744-3198

Fax: 1-866-744-3303

Monday–Friday 8:00 AM–8:00 PM (Eastern Time)

Indication

- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed

Important Safety Information

- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- In clinical studies, the most common solicited adverse reactions were pain at the injection site ($\geq 85\%$), fatigue ($\geq 40\%$), headache ($\geq 35\%$), muscle pain ($\geq 30\%$), and chills ($\geq 15\%$)
- Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness has not been established in pregnant women

Click [here](#) for full Prescribing Information for TRUMENBA.

